Director/PDMR Shareholding
05/04/2024 15:39
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240405:nRSE5584Ja&default-theme=true
RNS Number : 5584J Evgen Pharma PLC 05 April 2024
Evgen Pharma plc
("Evgen", the "Company" or the "Group")
Director / PDMR Shareholding
5 April 2024 - Evgen Pharma plc (AIM: EVG), the clinical stage drug
development company developing sulforaphane based medicines for the treatment
of multiple diseases, announces that certain Directors and Persons
Discharging Managerial Responsibility ("PDMRs") have subscribed for new
Ordinary Shares amounting to an aggregate subscription for 8,600,000 new
Ordinary Shares through the Placing or the Subscription or pursuant to the
terms of the Acquisition announced on 19 March 2024, as follows:
Director Number of Existing Ordinary Shares held Number of New Ordinary Shares being subscribed Number of Initial Consideration Shares being allotted pursuant to the Total number of Ordinary Shares immediately following Admission Percentage of Issued Share Capital following Admission
Acquisition
Dr Huw Jones (CEO) 62,500 3,000,000 122,293** 3,184,793 0.75%
Toni Hänninen (CFO)* 0 1,000,000 0 1,000,000 0.23%
Dr Susan Foden (Chair) 125,000 600,000 0 725,000 0.17%
Dr Helen Kuhlman (PDMR) 55,744 1,000,000 0 1,055,744 0.25%
Dr Glen Clack (PDMR)*** 0 1,000,000 0 1,000,000 0.23%
Dr Nicholas Mallard (PDMR) 20,771 2,000,000 0 2,020,771 0.47%
*Toni Hänninen participated via Borealito GmbH (a company wholly owned by
him).
** Dr Huw Jones has a shareholding of 96,350 shares in Chronos Therapeutics
and will as result be receiving 122,293 Initial Consideration Shares in Evgen
on completion of the Acquisition.
***Dr Glen Clack participated via Ailse Oncology Ltd (a company wholly owned
by him).
Unless otherwise defined herein, terms used in this announcement have the
meaning given to them in the Acquisition, Fundraising and Change of Name
announcement dated 19 March 2024.
Enquiries
Evgen Pharma plc +44 207 457 2020
Dr Huw Jones, CEO
enquiries@evgen.com
Toni Hänninen, CFO
Dr Helen Kuhlman, CBO
Cavendish Capital Markets (NOMAD and Broker) +44 20 7220 0500
Geoff Nash / Teddy Whiley / Rory Sale (Corporate Finance)
Nigel Birks / Harriet Ward (ECM)
Instinctif Partners +44 207 457 2020
Evgen@Instinctif.com
Melanie Toyne-Sewell / Jack Kincade
About Evgen Pharma plc
Evgen Pharma is a clinical stage drug development company developing
sulforaphane based medicines for the treatment of multiple diseases. The
Company's core technology is Sulforadex®, a method for synthesising and
stabilising the highly biologically active compound sulforaphane and novel
proprietary analogues based on sulforaphane.
The Company's lead asset, SFX-01, is a patented composition of synthetic
sulforaphane and alpha-cyclodextrin and has undergone clinical trials for
oestrogen-positive (ER+) metastatic breast cancer and recently a Phase 1b
study of the Company's new enteric coated tablet formulation. The FDA has
granted Orphan Drug status to SFX-01 in malignant glioma. SFX-01 will be
investigated initially in this indication as an investigator sponsored study
in the Netherlands.
The Company also has a wide number of collaborations with leading academic
centres in the UK, Europe and the US as part of the continuing strategy to
build the scientific data for the compound. Recently, Evgen completed an
out-licensing transaction with Stalicla SA, a Swiss specialist company in
neurodevelopmental disorders, commencing with autism spectrum disorder. The
deal, if successful, will generate milestone payments of $160.5m and a
double-digit royalty on sales.
The Company has its headquarters and registered office at Alderley
Park, Cheshire. It is listed on AIM in London and trades under the ticker
symbol EVG.
For further information, please visit: www.evgen.com (http://www.evgen.com/)
.
Accordingly, the Company makes the following announcement and notification in
accordance with the EU Market Abuse Regulation (No 596/2014):
1. Details of the person discharging managerial responsibilities / person closely
associated
a) Name Dr Huw Jones
2. Reason for the Notification
a) Position/status Chief Executive Officer
b) Initial notification/Amendment Initial Notification
3. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Evgen Pharma plc
b) LEI 213800NO3E6TSTQO8K20
4. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the Financial instrument, type of instrument
Ordinary Shares of 0.25p each
Identification code GB00BSVYN304
b) Nature of the transaction Purchase of new Ordinary Shares and receipt of Consideration Shares
c) Price(s) and volume(s) Type Price(s) Volume(s)
Initial Consideration Shares 1.44p 122,293
Placing Shares 1p 3,000,000
d) Aggregated information: As above
· Aggregated volume
· Price
e) Date of the transaction 5 April 2024
f) Place of the transaction London Stock Exchange, AIM Market
d)
Aggregated information:
· Aggregated volume
· Price
As above
e)
Date of the transaction
5 April 2024
f)
Place of the transaction
London Stock Exchange, AIM Market
1. Details of the person discharging managerial responsibilities / person closely
associated
a) Name Toni Hänninen
2. Reason for the Notification
a) Position/status Chief Financial Officer
b) Initial notification/Amendment Initial Notification
3. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Evgen Pharma plc
b) LEI 213800NO3E6TSTQO8K20
4. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the Financial instrument, type of instrument
Ordinary Shares of 0.25p each
Identification code GB00BSVYN304
b) Nature of the transaction Purchase of new Ordinary Shares
c) Price(s) and volume(s) Price(s) Volume(s)
1p 1,000,000
d) Aggregated information: As above
· Aggregated volume
· Price
e) Date of the transaction 5 April 2024
f) Place of the transaction London Stock Exchange, AIM Market
d)
Aggregated information:
· Aggregated volume
· Price
As above
e)
Date of the transaction
5 April 2024
f)
Place of the transaction
London Stock Exchange, AIM Market
1. Details of the person discharging managerial responsibilities / person closely
associated
a) Name Dr Susan Foden
2. Reason for the Notification
a) Position/status Non-Executive Chair
b) Initial notification/Amendment Initial Notification
3. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Evgen Pharma plc
b) LEI 213800NO3E6TSTQO8K20
4. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the Financial instrument, type of instrument
Ordinary Shares of 0.25p each
Identification code GB00BSVYN304
b) Nature of the transaction Purchase of new Ordinary Shares
c) Price(s) and volume(s) Price(s) Volume(s)
1p 600,000
d) Aggregated information: As above
· Aggregated volume
· Price
e) Date of the transaction 5 April 2024
f) Place of the transaction London Stock Exchange, AIM Market
d)
Aggregated information:
· Aggregated volume
· Price
As above
e)
Date of the transaction
5 April 2024
f)
Place of the transaction
London Stock Exchange, AIM Market
1. Details of the person discharging managerial responsibilities / person closely
associated
a) Name Dr Helen Kuhlman
2. Reason for the Notification
a) Position/status Chief Business Office / PDMR
b) Initial notification/Amendment Initial Notification
3. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Evgen Pharma plc
b) LEI 213800NO3E6TSTQO8K20
4. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the Financial instrument, type of instrument
Ordinary Shares of 0.25p each
Identification code GB00BSVYN304
b) Nature of the transaction Purchase of new Ordinary Shares
c) Price(s) and volume(s) Price(s) Volume(s)
1p 1,000,000
d) Aggregated information: As above
· Aggregated volume
· Price
e) Date of the transaction 5 April 2024
f) Place of the transaction London Stock Exchange, AIM Market
d)
Aggregated information:
· Aggregated volume
· Price
As above
e)
Date of the transaction
5 April 2024
f)
Place of the transaction
London Stock Exchange, AIM Market
1. Details of the person discharging managerial responsibilities / person closely
associated
a) Name Glen Clack
2. Reason for the Notification
a) Position/status Chief Medical Officer / PDMR
b) Initial notification/Amendment Initial Notification
3. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Evgen Pharma plc
b) LEI 213800NO3E6TSTQO8K20
4. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the Financial instrument, type of instrument
Ordinary Shares of 0.25p each
Identification code GB00BSVYN304
b) Nature of the transaction Purchase of new Ordinary Shares
c) Price(s) and volume(s) Price(s) Volume(s)
1p 1,000,000
d) Aggregated information: As above
· Aggregated volume
· Price
e) Date of the transaction 5 April 2024
f) Place of the transaction London Stock Exchange, AIM Market
d)
Aggregated information:
· Aggregated volume
· Price
As above
e)
Date of the transaction
5 April 2024
f)
Place of the transaction
London Stock Exchange, AIM Market
1. Details of the person discharging managerial responsibilities / person closely
associated
a) Name Dr Nicholas Mallard
2. Reason for the Notification
a) Position/status PDMR
b) Initial notification/Amendment Initial Notification
3. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Evgen Pharma plc
b) LEI 213800NO3E6TSTQO8K20
4. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the Financial instrument, type of instrument
Ordinary Shares of 0.25p each
Identification code GB00BSVYN304
b) Nature of the transaction Purchase of new Ordinary Shares
c) Price(s) and volume(s) Price(s) Volume(s)
1p 2,000,000
d) Aggregated information: As above
· Aggregated volume
· Price
e) Date of the transaction 5 April 2024
f) Place of the transaction London Stock Exchange, AIM Market
d)
Aggregated information:
· Aggregated volume
· Price
As above
e)
Date of the transaction
5 April 2024
f)
Place of the transaction
London Stock Exchange, AIM Market
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END DSHQKPBNQBKDPQK